Neurogene Inc. Finance Lease, Right-of-Use Asset, Amortization
Neurogene Inc. (NGNE) reported Finance Lease, Right-of-Use Asset, Amortization of $7.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-11
- Neurogene Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $7.00K, a 41.67% decline year-over-year.
- Neurogene Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $7.00K, a 46.15% decline year-over-year.
- Neurogene Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $11.00K, a 15.38% decline year-over-year.
- Neurogene Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $12.00K, a 0.00% change year-over-year.
- Neurogene Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $49.00K, a 5.77% decline from fiscal 2024.
- Neurogene Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $52.00K, a 48.57% increase from fiscal 2023.
- Neurogene Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $35.00K, a 775.00% increase from fiscal 2022.
- Neurogene Inc. finance lease, right-of-use asset, amortization for fiscal 2022 was $4.00K, a 91.84% decline from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month | Finance Lease, Right-of-Use Asset, Amortization 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $7.00K 10-Q · filed 2026-08-11 | $14.00K 10-Q · filed 2026-08-11 | $25.00K derived: sum of 3 quarters · filed 2026-08-11 | $37.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $7.00K 10-Q · filed 2026-05-12 | $18.00K derived: sum of 2 quarters · filed 2026-05-12 | $30.00K derived: sum of 3 quarters · filed 2026-05-12 | $42.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $23.00K derived: sum of 2 quarters · filed 2026-03-24 | $35.00K derived: sum of 3 quarters · filed 2026-08-11 | $49.00K 10-K · filed 2026-03-24 | |
| 2025-09-30 | $12.00K 10-Q · filed 2025-11-13 | $24.00K derived: sum of 2 quarters · filed 2026-08-11 | $38.00K 10-Q · filed 2025-11-13 | $50.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $12.00K 10-Q · filed 2026-08-11 | $26.00K 10-Q · filed 2026-08-11 | $38.00K derived: sum of 3 quarters · filed 2026-08-11 | $50.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $13.00K 10-Q · filed 2026-05-12 | $26.00K derived: sum of 2 quarters · filed 2026-05-12 | $38.00K derived: sum of 3 quarters · filed 2026-05-12 | $55.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $25.00K derived: sum of 2 quarters · filed 2026-03-24 | $42.00K derived: sum of 3 quarters · filed 2026-03-24 | $52.00K 10-K · filed 2026-03-24 | |
| 2024-09-30 | $12.00K 10-Q · filed 2025-11-13 | $29.00K derived: sum of 2 quarters · filed 2025-11-13 | $39.00K 10-Q · filed 2025-11-13 | $51.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $17.00K 10-Q · filed 2025-08-11 | $27.00K 10-Q · filed 2025-08-11 | $39.00K derived: sum of 3 quarters · filed 2025-08-11 | $49.00K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $11.00K 10-Q · filed 2025-05-09 | $22.00K derived: sum of 2 quarters · filed 2025-05-09 | $32.00K derived: sum of 3 quarters · filed 2025-05-09 | $40.00K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $21.00K derived: sum of 2 quarters · filed 2025-03-24 | $29.00K derived: sum of 3 quarters · filed 2025-03-24 | $35.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $10.00K 10-Q · filed 2024-11-18 | $18.00K derived: sum of 2 quarters · filed 2024-11-18 | $24.00K 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | $8.00K 10-Q · filed 2024-08-09 | $14.00K 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $6.00K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $4.00K 10-K · filed 2024-03-18 | $58.00K 10-K · filed 2023-03-20 | |||
| 2021-12-31 | $49.00K 10-K · filed 2023-03-20 | ||||
| 2020-12-31 | $46.00K 10-K · filed 2022-03-01 | ||||
| 2020-03-31 | $12.00K 10-Q · filed 2020-05-06 | $24.00K derived: sum of 2 quarters · filed 2021-03-25 | $31.00K derived: sum of 3 quarters · filed 2021-03-25 | ||
| 2019-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $19.00K derived: sum of 2 quarters · filed 2021-03-25 | $19.00K 10-K · filed 2021-03-25 | ||
| 2019-09-30 | $7.00K 10-Q · filed 2019-11-13 | $7.00K 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |